Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed/refractory multiple myeloma


Por: Jimenez-Segura, R, Granell, M, Gironella, M, Abella, E, Garcia-Guinon, A, Oriol, A, Cabezudo, E, Clapes, V, Soler, JA, Escoda, L, Lopez-Pardo, J, de Larrea, CF, Cibeira, MT, Tovar, N, Isola, I, Blade, J and Rosinol, L

Publicada: 1 may 2019 Ahead of Print: 25 feb 2019
Resumen:
Objective The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide-dexamethasone combination in this patient profile. Method In the present study, the efficacy of pomalidomide and dexamethasone in 21 patients from nine hospitals of Catalonia (Spain), with relapsed or refractory MM and Ps, was analyzed. For this purpose, we describe the evolution of paraprotein in serum and urine and the size of plasmacytomas during treatment with pomalidomide-dexamethasone. Results While 34% of the patients achieved a paraprotein response, only two patients with PPs (9%) responded (RC and PR). There were no responses among patients with EMPs. The median progression-free survival from the start of treatment with pomalidomide/dexamethasone was only 1.7 months and the median overall survival of 4.5 months. Conclusion In conclusion, pomalidomide and dexamethasone has limited efficacy in patients with advanced MM and soft-tissue plasmacytomas.

Filiaciones:
Jimenez-Segura, R:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Granell, M:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

Gironella, M:
 Hosp Univ Vall dHebron, Barcelona, Spain

Abella, E:
 Hosp del Mar, Barcelona, Spain

Garcia-Guinon, A:
 Hosp Arnau Vilanova, Lleida, Spain

:
 Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

Cabezudo, E:
 Hosp St Joan de Deu Manresa, Barcelona, Spain

Clapes, V:
 Inst Catalan Oncol Hospitalet Llobregat, Barcelona, Spain

Soler, JA:
 Hosp Parc Tauli Sabadell, Barcelona, Spain

Escoda, L:
 Hosp Univ Joan XXIII, Tarragona, Spain

Lopez-Pardo, J:
 Hosp Santa Creu & Sant Pau, Barcelona, Spain

de Larrea, CF:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Cibeira, MT:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Tovar, N:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Isola, I:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Blade, J:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

Rosinol, L:
 Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
ISSN: 09024441





European Journal of Haematology
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 102 Número: 5
Páginas: 389-394
WOS Id: 000466420400002
ID de PubMed: 30719772

MÉTRICAS